On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin | Zendy

Christopher B. Fordyce | Zendy; Anne S. Hellkamp | Zendy; Yuliya Lokhnygina | Zendy; Samuel M. Lindner | Zendy; Jonathan P. Piccini | Zendy; Richard C. Becker | Zendy; Scott D. Berkowitz | Zendy; Günter Breithardt | Zendy; Keith A.A. Fox | Zendy; Kenneth W. Mahaffey | Zendy; Christopher C. Nessel | Zendy; Daniel E. Singer | Zendy; Manesh R. Patel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin

Author(s) -

Christopher B. Fordyce,

Anne S. Hellkamp,

Yuliya Lokhnygina,

Samuel M. Lindner,

Jonathan P. Piccini,

Richard C. Becker,

Scott D. Berkowitz,

Günter Breithardt,

Keith A.A. Fox,

Kenneth W. Mahaffey,

Christopher C. Nessel,

Daniel E. Singer,

Manesh R. Patel

Publication year - 2016

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.116.021890

Subject(s) - rivaroxaban , medicine , warfarin , stroke (engine) , atrial fibrillation , renal function , embolism , cardiology , hazard ratio , randomized controlled trial , myocardial infarction , confidence interval , mechanical engineering , engineering

Despite rapid clinical adoption of novel anticoagulants, it is unknown whether outcomes differ among patients with worsening renal function (WRF) taking these new drugs compared with warfarin. We aimed to determine whether the primary efficacy (stroke or systemic embolism) and safety (major bleeding and nonmajor clinically relevant bleeding) end points from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial) differed among participants with WRF taking rivaroxaban and those taking warfarin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research